ARS PHARMACEUTICALS INC (SPRY) Earnings History & Surprises
NASDAQ:SPRY • US82835W1080
9.04 USD
+0.17 (+1.92%)
At close: Mar 4, 2026
9.04 USD
0 (0%)
After Hours: 3/4/2026, 4:30:02 PM
Past quarterly earnings results for ARS PHARMACEUTICALS INC (SPRY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$0.45
Revenue Estimate26.095M
Last Reported
Release DateNov 10, 2025
PeriodQ3 / 2025
EPS Reported-$0.52
EPS Surprise -8.01%
Revenue Surprise 10.06%
Beat Rate
31%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.52 | -0.48 | -8.01% | -160.00% | 32.501M | 29.531M | 10.06% | 1,471.62% |
| Q2 2025 | -0.46 | -0.48 | 4.05% | -253.85% | 15.717M | 14.052M | 11.85% | 3,043.40% |
| Q1 2025 | -0.35 | -0.35 | 1.02% | -218.18% | 7.973M | 7.631M | 4.48% | - |
| Q4 2024 | 0.49 | -0.14 | 443.14% | 800.00% | 86.581M | 16.134M | 436.64% | - |
| Q3 2024 | -0.20 | -0.15 | -32.93% | -25.00% | 2.068M | 586.5K | 252.60% | - |
| Q2 2024 | -0.13 | -0.12 | -9.24% | 27.78% | 500K | 1.02M | -50.98% | 4,900.00% |
| Q1 2024 | -0.11 | -0.11 | 1.96% | 31.25% | - | -100.00% | ||
| Q4 2023 | -0.07 | -0.14 | 50.98% | -109.09% | - | -100.00% | ||
| Q3 2023 | -0.16 | -0.19 | 14.13% | 68.00% | - | - | ||
| Q2 2023 | -0.18 | -0.18 | -1.61% | 67.27% | 10K | - | - | |
| Q1 2023 | -0.16 | -0.17 | 6.45% | 77.14% | 20K | - | - | |
| Q4 2022 | 0.77 | -0.13 | 680.69% | 214.93% | 1.32M | 96.39K | 1,269.44% | - |
| Q3 2022 | -0.50 | -0.36 | -38.08% | 23.08% | - | - | ||
| Q2 2022 | -0.55 | -0.49 | -11.56% | 21.43% | - | - | ||
| Q1 2022 | -0.70 | -0.55 | -28.04% | -29.63% | - | - | ||
| Q4 2021 | -0.67 | -0.72 | 6.43% | 51.09% | - | - | ||
| Q3 2021 | -0.65 | -0.69 | 5.45% | - | - | - | ||
| Q2 2021 | -0.70 | -0.54 | -28.68% | - | - | - | ||
| Q1 2021 | -0.54 | -0.36 | -49.13% | - | - | - | ||
| Q4 2020 | -1.37 | -0.50 | -174.11% | - | - | - | ||
| Q3 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
110.05%
Max EPS beat (4)
443.14%
Min EPS beat (4)
-8.01%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
115.76%
Max Revenue beat (4)
436.64%
Min Revenue beat (4)
4.48%
Analysis
In the last 4 quarters, SPRY has beaten EPS estimates in 3 out of 4 releases
SPRY has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, SPRY has beaten the EPS estimates by 110.0% on average.
In the last 4 quarters, SPRY has beaten the revenue estimates by 115.8% on average.
ARS PHARMACEUTICALS INC / SPRY Earnings FAQ
Can you provide the last earnings date for ARS PHARMACEUTICALS INC?
ARS PHARMACEUTICALS INC (SPRY) last reported earnings on 11/10/2025.
Can you provide information on whether ARS PHARMACEUTICALS INC beat earnings estimates in the last quarter?
ARS PHARMACEUTICALS INC (SPRY) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often ARS PHARMACEUTICALS INC beats earnings estimates?
In the last 4 quarters, ARS PHARMACEUTICALS INC (SPRY) has beaten EPS estimates in 3 out of 4 releases.